May 5, 2026- Henry Schein, Inc. reported financial results for the first quarter ended March 28, 2026.
First Quarter 2026 Financial Results
- Total net sales for the quarter were $3.4 billion, an increase of 6.3% compared to the first quarter of 2025 and reflects 2.5% internal sales growth, 0.7% sales growth from acquisitions, and a 3.1% increase resulting from foreign currency exchange. First quarter sales growth is detailed in Exhibit A .
- Global Distribution and Value-Added Services sales for the quarter increased 6.1%, and reflects 2.5% internal sales growth, 0.6% sales growth from acquisitions, and a 3.0% increase resulting from foreign currency exchange compared with the first quarter of 2025. The main components are:
- Global Medical Distribution sales for the quarter increased 1.7%, and by 1.3% internal sales growth, compared with the first quarter of 2025.
- Global Value-Added Services sales for the quarter increased 10.6%, and by 7.8% internal sales growth, compared with the first quarter of 2025.
- Global Specialty Products sales for the quarter increased 8.1%, and by 1.7% internal sales growth, 1.7% sales growth from acquisitions, and a 4.7% increase resulting from foreign currency exchange, compared with the first quarter of 2025.
- Global Technology sales for the quarter increased 7.0%, and reflects 6.9% internal sales growth, 1.3% sales decrease due to a business disposal, and a 1.4% increase resulting from foreign currency exchange, compared with the first quarter of 2025.
- GAAP net income for the quarter was $107 million, or $0.92 per diluted shar , and compares with first-quarter 2025 GAAP net income of $110 million, or $0.88 per diluted share.
- Non-GAAP net income for the quarter was $153 million, or $1.32 per diluted share, and compares with first-quarter 2025 non-GAAP net income of $143 million, or $1.15 per diluted share.
- Adjusted EBITDA for the quarter was $289 million and compares with first-quarter 2025 Adjusted EBITDA of $259 million.
- In the first quarter of 2026, the Company acquired a controlling interest in its S.I.N. distributor in the U.S. to enhance its position in the value implant market and support its business integration strategy. This transaction resulted in a remeasurement gain of $11 million.